This will irreparably damage whatever credibility OPT has left....

This will irreparably damage whatever credibility OPT has left. The data will be severely compromised by bias, rendering it unusable, let alone sufficient for regulatory approval of a drug once projected to generate billions in revenue. The bullish case is effectively dead, and voluntary administration now appears to be the most likely outcome.